Analyst firms · Wells Fargo · APLS
Wells Fargo APLS price target and rating history
Apellis Pharmaceuticals Inc. (APLS) · Health Care
Wells Fargo rates Apellis Pharmaceuticals Inc. (APLS) Overweight with a $32 price target, as of its latest action on Oct 15, 2025. It has published 5 rating actions on APLS since December 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
- Current rating
- Overweight
- Price target
- $32
- Median target, all firms
- $28
- Actions on APLS
- 5
Wells Fargo price target on APLS
Every Wells Fargo rating on APLS
- Oct 15, 2025
- Dec 14, 2023
- Sep 15, 2023
- Jan 3, 2023
- Dec 8, 2021
How other firms rate APLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $31 | Mar 13, 2026 |
| Barclays | Equal Weight | $24 | Jan 28, 2026 |
| BofA Securities | Buy | $28 | Jan 21, 2026 |
Questions about Wells Fargo and APLS
- What is Wells Fargo's price target for APLS?
- Wells Fargo's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $32, from its action on Oct 15, 2025.
- What is Wells Fargo's rating on APLS?
- Wells Fargo rates APLS Overweight, a bullish rating, as of Oct 15, 2025.
- When did Wells Fargo last change its view on APLS?
- On Oct 15, 2025, Wells Fargo starts coverage at Overweight, price target $32.
- How does Wells Fargo's APLS target compare with other analysts?
- Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
More APLS rating histories
All Wells Fargo ratingsAPLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.